Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/BIRC5_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BIRC5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BIRC5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BIRC5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BIRC5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BIRC5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005254714 | Breast | IDC | regulation of peptidase activity | 96/1434 | 461/18723 | 7.58e-20 | 6.15e-17 | 96 |
GO:005254814 | Breast | IDC | regulation of endopeptidase activity | 88/1434 | 432/18723 | 1.20e-17 | 4.85e-15 | 88 |
GO:200011614 | Breast | IDC | regulation of cysteine-type endopeptidase activity | 55/1434 | 235/18723 | 4.25e-14 | 1.21e-11 | 55 |
GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
GO:004328114 | Breast | IDC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 50/1434 | 209/18723 | 2.49e-13 | 6.14e-11 | 50 |
GO:005134613 | Breast | IDC | negative regulation of hydrolase activity | 71/1434 | 379/18723 | 1.33e-12 | 2.90e-10 | 71 |
GO:001046613 | Breast | IDC | negative regulation of peptidase activity | 56/1434 | 262/18723 | 1.39e-12 | 2.92e-10 | 56 |
GO:001095112 | Breast | IDC | negative regulation of endopeptidase activity | 52/1434 | 252/18723 | 3.53e-11 | 5.57e-09 | 52 |
GO:200011713 | Breast | IDC | negative regulation of cysteine-type endopeptidase activity | 25/1434 | 86/18723 | 3.31e-09 | 2.77e-07 | 25 |
GO:004315413 | Breast | IDC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 22/1434 | 78/18723 | 5.26e-08 | 3.32e-06 | 22 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
GO:003150314 | Esophagus | ESCC | protein-containing complex localization | 139/8552 | 220/18723 | 1.14e-07 | 1.85e-06 | 139 |
GO:2000117110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity | 63/8552 | 86/18723 | 1.84e-07 | 2.88e-06 | 63 |
GO:0043154110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 58/8552 | 78/18723 | 2.38e-07 | 3.61e-06 | 58 |
GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BIRC5 | SNV | Missense_Mutation | rs146071276 | c.253N>C | p.Thr85Pro | p.T85P | | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
BIRC5 | SNV | Missense_Mutation | | c.292N>C | p.Glu98Gln | p.E98Q | | protein_coding | tolerated(0.16) | benign(0.033) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
BIRC5 | SNV | Missense_Mutation | novel | c.11C>T | p.Pro4Leu | p.P4L | | protein_coding | tolerated(0.11) | benign(0.047) | TCGA-VS-A9V3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
BIRC5 | SNV | Missense_Mutation | rs267605071 | c.76C>T | p.Pro26Ser | p.P26S | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
BIRC5 | SNV | Missense_Mutation | | c.38N>C | p.Phe13Ser | p.F13S | | protein_coding | tolerated(0.05) | benign(0.01) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
BIRC5 | SNV | Missense_Mutation | rs115296168 | c.227N>T | p.Pro76Leu | p.P76L | | protein_coding | tolerated_low_confidence(0.1) | possibly_damaging(0.859) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BIRC5 | SNV | Missense_Mutation | | c.220N>G | p.Ile74Val | p.I74V | | protein_coding | tolerated(0.73) | benign(0.006) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BIRC5 | SNV | Missense_Mutation | | c.230N>A | p.Gly77Asp | p.G77D | | protein_coding | tolerated_low_confidence(0.32) | benign(0.09) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BIRC5 | SNV | Missense_Mutation | rs201354179 | c.452N>T | p.Ala151Val | p.A151V | | protein_coding | tolerated(0.34) | probably_damaging(0.923) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BIRC5 | SNV | Missense_Mutation | | c.196G>T | p.Gly66Cys | p.G66C | | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-55-8511-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | GM-CSF | REGRAMOSTIM | 16403261 |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | VIOXX | ROFECOXIB | 14627349 |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | EZN-3042 | | |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | PLATINUM COMPOUND | | 24961465 |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | EPIRUBICIN | EPIRUBICIN | 16608080 |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | ATRA | TRETINOIN | 14587026,16403261 |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | CV-9201 | | |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | SurVaxM | | |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | CANCER VACCINE | | 15746049 |
332 | BIRC5 | DRUG RESISTANCE, TUMOR SUPPRESSOR, PROTEASE INHIBITOR, DRUGGABLE GENOME | | ENZYME INHIBITOR | | 17059765 |